Immunodetection of human topoisomerase I-DNA covalent complexes

Systematic Review of topotecan (Hycamtin) in relapsed small cell lung cancer

(2016) Rob Riemsma et al.   BMC CANCER

DNA–protein crosslink repair: proteases as DNA repair enzymes

(2015) Julian Stingele et al.   TRENDS IN BIOCHEMICAL SCIENCES

A DNA-Dependent Protease Involved in DNA-Protein Crosslink Repair

(2014) Julian Stingele et al.   CELL

Tyrosyl-DNA-phosphodiesterases (TDP1 and TDP2)

(2014) Yves Pommier et al.   DNA REPAIR

Tyrosyl-DNA phosphodiesterase I resolves both naturally and chemically induced DNA adducts and its potential as a therapeutic target

(2014) Evan Q. Comeaux et al.   DRUG METABOLISM REVIEWS

Macromolecular Prodrug That Provides the Irinotecan (CPT-11) Active-Metabolite SN-38 with Ultralong Half-Life, Low Cmax , and Low Glucuronide Formation

(2014) Daniel V. Santi et al.   JOURNAL OF MEDICINAL CHEMISTRY

Ultrasensitive isolation, identification and quantification of DNA–protein adducts by ELISA-based RADAR assay

(2014) Kostantin Kiianitsa et al.   NUCLEIC ACIDS RESEARCH

A systematic review on topoisomerase 1 inhibition in the treatment of metastatic breast cancer

(2013) Iben Kümler et al.   BREAST CANCER RESEARCH AND TREATMENT

Camptothecin Resistance in Cancer: Insights into the Molecular Mechanisms of a DNA-Damaging Drug

(2013) G. L. Beretta et al.   CURRENT MEDICINAL CHEMISTRY

Topoisomerase inhibitors as anticancer agents: a patent update

(2013) Daulat B Khadka et al.   EXPERT OPINION ON THERAPEUTIC PATENTS

Targeting DNA Topoisomerase I with Non-Camptothecin Poisons

(2012) G. L. Beretta et al.   CURRENT MEDICINAL CHEMISTRY

Topoisomerase 1 Inhibitors and Cancer Therapy

(2012) Julia Moukharskaya et al.   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

Development and Validation of an Immunoassay for Quantification of Topoisomerase I in Solid Tumor Tissues

(2012) Thomas D. Pfister et al.   PLoS One

Cytotoxicity of farnesyltransferase inhibitors in lymphoid cells mediated by MAPK pathway inhibition and Bim up-regulation

(2011) H. Ding et al.   BLOOD

SHP-1 expression accounts for resistance to imatinib treatment in Philadelphia chromosome-positive cells derived from patients with chronic myeloid leukemia

(2011) N. Esposito et al.   BLOOD

Topoisomerase I inhibition in colorectal cancer: biomarkers and therapeutic targets

(2011) D C Gilbert et al.   BRITISH JOURNAL OF CANCER

New Strategies in the Discovery of Novel Non-Camptothecin Topoisomerase I Inhibitors

(2011) Chunquan Sheng et al.   CURRENT MEDICINAL CHEMISTRY

Preclinical and clinical activity of the topoisomerase I inhibitor, karenitecin, in melanoma

(2011) Pamela N Munster et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Enhanced Killing of Cancer Cells by Poly(ADP-ribose) Polymerase Inhibitors and Topoisomerase I Inhibitors Reflects Poisoning of Both Enzymes

(2011) Anand G. Patel et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Poly(ADP-ribose) polymerase and XPF–ERCC1 participate in distinct pathways for the repair of topoisomerase I-induced DNA damage in mammalian cells

(2011) Yong-Wei Zhang et al.   NUCLEIC ACIDS RESEARCH

Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells

(2011) A. G. Patel et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

DNA Topoisomerases and Their Poisoning by Anticancer and Antibacterial Drugs

(2010) Yves Pommier et al.   CHEMISTRY & BIOLOGY

Development of a Validated Immunofluorescence Assay for  H2AX as a Pharmacodynamic Marker of Topoisomerase I Inhibitor Activity

(2010) R. J. Kinders et al.   CLINICAL CANCER RESEARCH

Cancer Therapies Utilizing the Camptothecins: A Review of thein VivoLiterature

(2010) Vincent J. Venditto et al.   MOLECULAR PHARMACEUTICS

XMT-1001, a novel polymeric camptothecin pro-drug in clinical development for patients with advanced cancer

(2009) Alexander V. Yurkovetskiy et al.   ADVANCED DRUG DELIVERY REVIEWS

Novel camptothecin derivatives as topoisomerase I inhibitors

(2009) Serena Basili et al.   EXPERT OPINION ON THERAPEUTIC PATENTS